spacer
home > ict > summer 2019 > finding the right fit
PUBLICATIONS
International Clinical Trials

Finding the Right Fit





ICT: Is it preferable to partner with a small, large, or mid-size CRO?

Catherine Konidas: It depends on whether you want to deal with a large company or would prefer having a more direct involvement in your projects. In many cases, mid-size companies may be more flexible, agile, and open to adapting their processes to meet your requirements. The culture of a mid-size organisation usually emphasises responsiveness and client relationships, regardless of the size of your business or programme budget.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Catherine Konidas joined Altasciences in 2010 as Vice President of Global Business Development, with the mandate of building a high-performing business development team focused on transforming the company’s commercial offering to cater to the expanding innovator market. Catherine was promoted to Chief Commercial Officer in 2017 and now oversees the company’s commercial strategy, including mergers and acquisitions activity, corporate budgeting, and overall business metrics across the organisation. She started her career at CTBR Bio-Research (now Charles River Laboratories) in 2002, holding a series of positions of increasing responsibility in business development before being appointed Senior Site Director of the Montreal facility, Canada, and leading approximately 1,300 employees. She holds a BA in Psychology and a Master’s in Business Administration.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement